Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab

Giorgia Bodini; Vincenzo Savarino; Laurent Peyrin-Biroulet; Chiara de Cassan; Pietro Dulbecco; Isabella Baldissarro; Valentina Fazio; Elisa Giambruno; Edoardo Savarino

doi:10.1016/j.dld.2014.07.171

Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab

Giorgia Bodini, Vincenzo Savarino, Laurent Peyrin-Biroulet, Chiara de Cassan, Pietro Dulbecco, Isabella Baldissarro, Valentina Fazio, Elisa Giambruno, Edoardo Savarino

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Whether therapeutic drug monitoring of biologic therapy can predict the efficacy of adalimumab to prevent postoperative Crohn's disease recurrence is unknown. Aim: To investigate whether adalimumab trough levels and anti-adalimumab antibodies correlate with endoscopic and clinical outcomes in a series of patients treated with prophylactic adalimumab monotherapy after resective surgery. Methods: Post hoc analysis of a randomized, mesalamine-controlled trial. Adalimumab trough levels and antibodies were analysed every 8 weeks for 2 years using an homogeneous mobility shift assay. Results: At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence. At baseline (9.5 vs. 14.4. mcg/mL) and during follow-up [7.5 (4.4-9.8) vs. 13.9 (8.9-23.6). mcg/mL, p

Original language	English
Pages (from-to)	1043-1046
Number of pages	4
Journal	Digestive and Liver Disease
Volume	46
Issue number	11
DOIs	https://doi.org/10.1016/j.dld.2014.07.171
Publication status	Published - Nov 1 2014

Keywords

Adalimumab
Anti-tumour necrosis factor alpha antibodies
Crohn's disease
Post-surgical recurrence

ASJC Scopus subject areas

Gastroenterology
Hepatology
Medicine(all)

Access to Document

10.1016/j.dld.2014.07.171

Fingerprint Dive into the research topics of 'Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab'. Together they form a unique fingerprint.

Cite this

Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. / Bodini, Giorgia; Savarino, Vincenzo; Peyrin-Biroulet, Laurent; de Cassan, Chiara; Dulbecco, Pietro; Baldissarro, Isabella; Fazio, Valentina; Giambruno, Elisa; Savarino, Edoardo.

In: Digestive and Liver Disease, Vol. 46, No. 11, 01.11.2014, p. 1043-1046.

Research output: Contribution to journal › Article › peer-review

Bodini, G, Savarino, V, Peyrin-Biroulet, L, de Cassan, C, Dulbecco, P, Baldissarro, I, Fazio, V, Giambruno, E & Savarino, E 2014, 'Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab', Digestive and Liver Disease, vol. 46, no. 11, pp. 1043-1046. https://doi.org/10.1016/j.dld.2014.07.171

Bodini, Giorgia ; Savarino, Vincenzo ; Peyrin-Biroulet, Laurent ; de Cassan, Chiara ; Dulbecco, Pietro ; Baldissarro, Isabella ; Fazio, Valentina ; Giambruno, Elisa ; Savarino, Edoardo. / Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. In: Digestive and Liver Disease. 2014 ; Vol. 46, No. 11. pp. 1043-1046.

@article{ba8a58a082ee4ae7867c7acb4d6b7b2f,

title = "Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab",

abstract = "Background: Whether therapeutic drug monitoring of biologic therapy can predict the efficacy of adalimumab to prevent postoperative Crohn's disease recurrence is unknown. Aim: To investigate whether adalimumab trough levels and anti-adalimumab antibodies correlate with endoscopic and clinical outcomes in a series of patients treated with prophylactic adalimumab monotherapy after resective surgery. Methods: Post hoc analysis of a randomized, mesalamine-controlled trial. Adalimumab trough levels and antibodies were analysed every 8 weeks for 2 years using an homogeneous mobility shift assay. Results: At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence. At baseline (9.5 vs. 14.4. mcg/mL) and during follow-up [7.5 (4.4-9.8) vs. 13.9 (8.9-23.6). mcg/mL, p",

keywords = "Adalimumab, Anti-tumour necrosis factor alpha antibodies, Crohn's disease, Post-surgical recurrence",

author = "Giorgia Bodini and Vincenzo Savarino and Laurent Peyrin-Biroulet and {de Cassan}, Chiara and Pietro Dulbecco and Isabella Baldissarro and Valentina Fazio and Elisa Giambruno and Edoardo Savarino",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/j.dld.2014.07.171",

language = "English",

volume = "46",

pages = "1043--1046",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab

AU - Bodini, Giorgia

AU - Savarino, Vincenzo

AU - Peyrin-Biroulet, Laurent

AU - de Cassan, Chiara

AU - Dulbecco, Pietro

AU - Baldissarro, Isabella

AU - Fazio, Valentina

AU - Giambruno, Elisa

AU - Savarino, Edoardo

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: Whether therapeutic drug monitoring of biologic therapy can predict the efficacy of adalimumab to prevent postoperative Crohn's disease recurrence is unknown. Aim: To investigate whether adalimumab trough levels and anti-adalimumab antibodies correlate with endoscopic and clinical outcomes in a series of patients treated with prophylactic adalimumab monotherapy after resective surgery. Methods: Post hoc analysis of a randomized, mesalamine-controlled trial. Adalimumab trough levels and antibodies were analysed every 8 weeks for 2 years using an homogeneous mobility shift assay. Results: At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence. At baseline (9.5 vs. 14.4. mcg/mL) and during follow-up [7.5 (4.4-9.8) vs. 13.9 (8.9-23.6). mcg/mL, p

AB - Background: Whether therapeutic drug monitoring of biologic therapy can predict the efficacy of adalimumab to prevent postoperative Crohn's disease recurrence is unknown. Aim: To investigate whether adalimumab trough levels and anti-adalimumab antibodies correlate with endoscopic and clinical outcomes in a series of patients treated with prophylactic adalimumab monotherapy after resective surgery. Methods: Post hoc analysis of a randomized, mesalamine-controlled trial. Adalimumab trough levels and antibodies were analysed every 8 weeks for 2 years using an homogeneous mobility shift assay. Results: At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence. At baseline (9.5 vs. 14.4. mcg/mL) and during follow-up [7.5 (4.4-9.8) vs. 13.9 (8.9-23.6). mcg/mL, p

KW - Adalimumab

KW - Anti-tumour necrosis factor alpha antibodies

KW - Crohn's disease

KW - Post-surgical recurrence

UR - http://www.scopus.com/inward/record.url?scp=84908215471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908215471&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2014.07.171

DO - 10.1016/j.dld.2014.07.171

M3 - Article

C2 - 25169962

AN - SCOPUS:84908215471

VL - 46

SP - 1043

EP - 1046

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 11

ER -

Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this